BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 17883595)

  • 1. Elevated tissue factor procoagulant activity in CD133-positive cancer cells.
    Milsom C; Anderson GM; Weitz JI; Rak J
    J Thromb Haemost; 2007 Dec; 5(12):2550-2. PubMed ID: 17883595
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical and biological significance of stem-like CD133(+)CXCR4(+) cells in esophageal squamous cell carcinoma.
    Lu C; Xu F; Gu J; Yuan Y; Zhao G; Yu X; Ge D
    J Thorac Cardiovasc Surg; 2015 Aug; 150(2):386-95. PubMed ID: 26092504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor-derived stem-cells and epithelial mesenchymal transition in squamous cell carcinoma in transplant recipients.
    Verneuil L; Leboeuf C; Bousquet G; Brugiere C; Elbouchtaoui M; Plassa LF; Peraldi MN; Lebbé C; Ratajczak P; Janin A
    Oncotarget; 2015 Dec; 6(39):41497-507. PubMed ID: 26594799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD133 and ABCB5 as stem cell markers on sentinel lymph node from melanoma patients.
    Gazzaniga P; Cigna E; Panasiti V; Devirgiliis V; Bottoni U; Vincenzi B; Nicolazzo C; Petracca A; Gradilone A
    Eur J Surg Oncol; 2010 Dec; 36(12):1211-4. PubMed ID: 20573479
    [No Abstract]   [Full Text] [Related]  

  • 5. Who cares about stem cells? We should!
    Ferraris VA
    J Thorac Cardiovasc Surg; 2015 Aug; 150(2):396-7. PubMed ID: 26055437
    [No Abstract]   [Full Text] [Related]  

  • 6. Progenitor stem cell marker expression by pulmonary carcinomas.
    Moreira AL; Gonen M; Rekhtman N; Downey RJ
    Mod Pathol; 2010 Jun; 23(6):889-95. PubMed ID: 20305619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Constitutive secretion of Interleukin-4 dictates CD133+ side population cells to resist drug treatment and cell death.
    Guan GF; Tang XX; Zhang DJ; Zheng Y; Yu DJ; Zhao Y; Lu YQ; Zhu L
    J BUON; 2015; 20(5):1350-9. PubMed ID: 26537085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic impact of CD133 expression in gastric carcinoma.
    Ishigami S; Ueno S; Arigami T; Uchikado Y; Setoyama T; Arima H; Kita Y; Kurahara H; Okumura H; Matsumoto M; Kijima Y; Natsugoe S
    Anticancer Res; 2010 Jun; 30(6):2453-7. PubMed ID: 20651407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma.
    Zhu Z; Hao X; Yan M; Yao M; Ge C; Gu J; Li J
    Int J Cancer; 2010 May; 126(9):2067-78. PubMed ID: 19711346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD133: a cancer stem cells marker, is used in colorectal cancers.
    Ren F; Sheng WQ; Du X
    World J Gastroenterol; 2013 May; 19(17):2603-11. PubMed ID: 23674867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Value of the Stem Cell Markers Epcam and CD133 Expression Of Gallbladder Adenocarcinoma.
    Jiang S; Pei L; Yang ZL; Liu G
    Hepatogastroenterology; 2014 May; 61(131):574-9. PubMed ID: 26176038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif.
    Taïeb N; Maresca M; Guo XJ; Garmy N; Fantini J; Yahi N
    Cancer Lett; 2009 Jun; 278(2):164-173. PubMed ID: 19216024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype.
    Srivastava VK; Nalbantoglu J
    Cytometry A; 2008 Oct; 73(10):940-8. PubMed ID: 18773455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Divergent expression of CD133 in different studies: the need for a consensus panel?
    Sgambato A; Errico F; Caredda E; Puglisi MA; Cittadini A
    Int J Cancer; 2011 May; 128(9):2247-9. PubMed ID: 20626045
    [No Abstract]   [Full Text] [Related]  

  • 15. Preclinical evaluation of Mab CC188 for ovarian cancer imaging.
    Xu M; Rettig MP; Sudlow G; Wang B; Akers WJ; Cao D; Mutch DG; DiPersio JF; Achilefu S
    Int J Cancer; 2012 Sep; 131(6):1351-9. PubMed ID: 22130973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the potential cancer stem cell markers CD133 and CD44 in medullary thyroid carcinoma: A ten-year follow-up and prognostic analysis.
    Bi Y; Meng Y; Wu H; Cui Q; Luo Y; Xue X
    J Surg Oncol; 2016 Feb; 113(2):144-51. PubMed ID: 26799258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres.
    Walter D; Satheesha S; Albrecht P; Bornhauser BC; D'Alessandro V; Oesch SM; Rehrauer H; Leuschner I; Koscielniak E; Gengler C; Moch H; Bernasconi M; Niggli FK; Schäfer BW;
    PLoS One; 2011; 6(5):e19506. PubMed ID: 21602936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional differences of miR-125b on the invasion of primary glioblastoma CD133-negative cells and CD133-positive cells.
    Shi L; Wan Y; Sun G; Gu X; Qian C; Yan W; Zhang S; Pan T; Wang Z; You Y
    Neuromolecular Med; 2012 Dec; 14(4):303-16. PubMed ID: 22711523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and characterization of tumor-initiating cells in human primary cutaneous squamous cell carcinoma.
    Patel GK; Yee CL; Terunuma A; Telford WG; Voong N; Yuspa SH; Vogel JC
    J Invest Dermatol; 2012 Feb; 132(2):401-9. PubMed ID: 22011906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD133(+) cells isolated from various sources and their role in future clinical perspectives.
    Meregalli M; Farini A; Belicchi M; Torrente Y
    Expert Opin Biol Ther; 2010 Nov; 10(11):1521-8. PubMed ID: 20932225
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.